REVB's Business Model
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.revbiosciences.com |
CEO (Chief Executive Officer) | James M. Rolke |
Number of Employees | |
IPO date | November 17, 2020 |
REVB Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 4660 La Jolla Village Drive |
City | San Diego |
State | CA |
Phone | 650-800-3717 |
Zip Code | 92122 |
Other Identifiers | |
CIK | 0001810560 |
ISIN | US76135L5075 |
CUSIP | 76135L101 |
Open | 2.5 |
Previous Close | 2.5797 |
Volume | 355.8 Thou. |
Average Volume | 378.4 Thou. |
Day’s Range | 2.45 – 2.5397 |
52 Week Range | 2.106-168 |
MA (50) | 5.27572 |
MA (200) | 18.70423 |
Market Cap | 1.7 Mil. |
Shares Out. | 676.6 Thou. |
Earnings Date | Aug 07, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |
Industry Competitors for REVB
Company
|
PE Ratio | Market Cap |
---|---|---|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|